2-(β-D-ribofuranosyl)adenin | 55628-61-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(β-D-ribofuranosyl)adenin
• 英文别名: (1S)-1-(6-amino-7(9)H-purin-2-yl)-D-1,4-anhydro-ribitol；beta-D-Ribofuranosyladenin；(2S,3R,4S,5R)-2-(6-amino-7H-purin-2-yl)-5-(hydroxymethyl)oxolane-3,4-diol
• CAS: 55628-61-0
• 化学式: C₁₀H₁₃N₅O₄
• 分子量: 267.244
• InChiKey: WIBJXLDWHFLFBG-SHUUEZRQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.1
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  150
• 氢给体数：
  5
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  (2Ξ)-O⁶-benzoyl-D-ribo-2,5-anhydro-hexonimidothioic acid benzyl ester 在 氨 作用下， 以 甲醇 为溶剂， 生成 2-(β-D-ribofuranosyl)adenin
  参考文献：
  名称：

  合成C 1-核苷。VII † β-D-呋喃呋喃糖基2和-8腺嘌呤

  摘要：

  莱斯环化杜盐酸盐代苄基（ø -苯甲酰基-5- d-D-呋喃核糖基）thioformimidate IV AVEE L'aminomalonitrile上L'氨基-5-氰基-4-咪唑donnent，滑雪后enlèvement杜groupement protecteur，LES Ç核苷类似物III等II德升'adénosine。光谱β光谱法（RMN，DC）。

  DOI：

  10.1002/jhet.5570120119

文献信息

• SUBSTITUTED ADENINES AND THE USES THEREOF
  申请人：Cavero-Tomas Marta

  公开号：US20090048203A1

  公开（公告）日：2009-02-19

  This invention relates to compounds of Formula (I): and their use in the treatment of bacterial infections.

  本发明涉及式(I)的化合物及其在治疗细菌感染方面的应用。
• [EN] METHODS OF PREPARING TARGETED APTAMER PRODRUGS<br/>[FR] PROCÉDÉS DE PRÉPARATION DE PROMÉDICAMENTS APTAMÈRES CIBLÉS
  申请人：EINSTEIN COLL MED

  公开号：WO2011142798A2

  公开（公告）日：2011-11-17

  The present invention provides methods of preparing an oligonucleotide, nucleoside or nucleoside analog for selective introduction into a subject's cells, the method comprising (1) selecting a targeted aptamer, internalizing nucleic acid or tumor-homing nucleic acid via iterative rounds of selection, and (i) hybridizing it to an oligonuceotide, (ii) replacing one or more nucleotide with a nucleoside or nucleoside analog, or (iii) synthesizing the it with one or more nucleoside or nucleoside analogs; or (2) preparing a naive combinatorial aptamer, internalizing nucleic acid or tumor-homing nucleic acid prodrug library, and running iterative rounds of selection for the cells. The present invention also provides the agent, the pharmaceutical composition, and methods of treating or preventing cancer and/or viral infection, the method comprising administration of the oligonuleotide, nucleoside or nucleoside analog for selective introduction into a subject's cells.
• [EN] TRANSFERRIN RECEPTOR APTAMERS AND APTAMER-TARGETED DELIVERY<br/>[FR] APTAMÈRES DU RÉCEPTEUR DE LA TRANSFERRINE ET ADMINISTRATION CIBLÉE D'APTAMÈRES
  申请人：EINSTEIN COLL MED

  公开号：WO2013163303A2

  公开（公告）日：2013-10-31

  Aptamers targeted to a human transferrin receptor which do not compete with transferrin for binding are provided. Compositions and methods for aptamer-targeted liposomal drug delivery are also provided.
• [EN] APTAMER-TARGETED ANTIGEN DELIVERY<br/>[FR] ADMINISTRATION D'ANTIGÈNE CIBLÉ À UN APTAMÈRE
  申请人：EINSTEIN COLL MED

  公开号：WO2014011465A2

  公开（公告）日：2014-01-16

  A composition is provided comprising an oligonucleotide aptamer conjugated to an antigen, wherein the aptamer is directed against a cell-surface target of an antigen- presenting cell. Also provided are methods of delivering an antigen to a dendritic cell and of eliciting an immune response in a subject.
• [EN] CHEMICALLY MODIFIED RNA APTAMERS AND USES THEREOF<br/>[FR] APTAMÈRES D'ARN CHIMIQUEMENT MODIFIÉS ET LEURS UTILISATIONS
  申请人：ALBERT EINSTEIN COLLEGE MEDICINE INC

  公开号：WO2018075264A1

  公开（公告）日：2018-04-26

  Provided are chemically modified ribonucleic acid (RNA) aptamers comprising one or more of 2'F guanylate, 2'OMe cytidylate, 2'OMe adenylate, and a deoxy pyrimidine nucleotide with a moiety on the 5 position of the pyrimidine; and methods of making the aptamers.